{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Monitor vital signs prior to and at the end of the infusion. Additional vital sign', 'monitoring may be performed in the event of infusion-associated AEs (see', 'Section 9.5.4.3 for details).', 'Administer study drug and record date, volume and rate of infusion, and start/stop times', 'of dosing.', 'Collect blood samples for PK analyses at the end of the infusion.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be contacted the following day to enquire about AEs and concomitant medication use.', 'Subjects will be instructed to return to the clinic at Week 4.', '9.5.6.4 Week 4', 'Collect blood samples for hematology and glucose testing (see Section 9.5.4.6 for details', 'concerning test results and study participation).', 'Collect blood sample for PK analyses. Record date/time of sample collection.', 'Collect vital signs.', 'Enquire about AEs and concomitant medication use.', 'Subjects will be released from the study center after all of the visit procedures have been', 'completed and instructed to return to the clinic at Week 6.', '9.5.6.5 Week 6', 'Obtain predose blood samples for hematology and chemistry (including thyroid, glucose,', 'but not HbA1c) analysis (see Section 9.5.4.6 for details concerning test results and study', 'participation).', 'Collect predose urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform predose 12-lead ECG.', 'Perform predose physical and ophthalmic examinations, including vital signs. Additional', 'vital sign monitoring may be performed in the event of infusion-associated AEs (see', 'Section 9.5.4.3 for details).', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 97 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Administer predose GO-QoL questionnaire.', 'Obtain study medication vial assignment and volume of study drug to be administered', 'from EDC.', 'Administer study drug and record date, volume and rate of infusion, and start/stop times', 'of dosing.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and instructed to return for a clinic visit at Week 9.', '9.5.6.6 Week 9', 'Obtain predose blood samples for hematology and chemistry (including thyroid, glucose,', 'but not HbAlc) analysis (see Section 9.5.4.6 for details concerning test results and study', 'participation).', 'Collect predose urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', 'Collect predose blood samples for immunogenicity and PK testing.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Collect predose vital signs. Additional vital sign monitoring may be performed in the', 'event of infusion-associated AEs (see Section 9.5.4.3 for details).', 'Obtain study medication vial assignment and volume of study drug to be administered', 'from EDC.', 'Administer study drug and record date, volume and rate of infusion, and start/stop times', 'of dosing.', 'Collect blood samples for PK analyses at the end of the infusion.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and instructed to return for a clinic visit at Week 12.', '9.5.6.7 Week 12', 'Obtain predose blood samples for hematology and chemistry (including thyroid, glucose,', 'and HbA1c) analysis (see Section 9.5.4.6 for details concerning test results and study', 'participation).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 98 of 118']\n\n###\n\n", "completion": "END"}